GlucoTrack, Inc., (GCTK) News
Filter GCTK News Items
GCTK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GCTK News From Around the Web
Below are the latest news stories about GLUCOTRACK INC that investors may wish to consider to help them evaluate GCTK as an investment opportunity.
GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITORRutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing. The Company previously announced the completion and positive results of a laboratory-based feasibility study |
GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORSRutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately. Ms. Carter brings 30 years of executive level finance experience in the medical device industry. From 2012 until March of 2023, she held va |
GLUCOTRACK ANNOUNCES NEW VP OF MARKETINGRutherford, NJ, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Drinda Benjamin has joined the company as Vice President of Marketing. Ms. Benjamin has over 20 years of experience in life sciences, with specific focus on commercialization of health technology. Within diabetes, she has past experiences in product deve |
The Power Play by The Market Herald Releases New Interviews with GlucoTrack and Acceleware Discussing Their Latest NewsThe Power Play by The Market Herald has announced the release of new interviews with GlucoTrack and Acceleware discussing their latest news. |
GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITORRutherford, NJ, July 25, 2023 (GLOBE NEWSWIRE) -- - Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The primary goal of the feasibility study was to demonstrate that the CGM sensor design could |
Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)Aegis Capital Corp. acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ:GCTK). |
GlucoTrack Closes $10 Million Underwritten Public Offering of Common StockRutherford, NJ, April 17, 2023 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced the closing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The offering consist |
GlucoTrack Announces Pricing of $10 Million Underwritten Public Offering of Common StockRutherford, NJ, April 13, 2023 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, today announced the pricing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company expected to be approximately $10 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The offering con |
GlucoTrack Announces Proposed Underwritten Public Offering of Common StockRutherford, NJ, April 12, 2023 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, today announced that it intends to offer shares of common stock in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, which may include, without limitation, engaging in acq |
GLUCOTRACK PROVIDES SHAREHOLDER UPDATERutherford, NJ, March 14, 2023 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter. To Our Valued Shareholders, At the outset, we would like to express our gratitude to all of our shareholders for their continued support of the Company. We remain fully comm |